Steven Dickman
Founder & Chief Executive Officer CBT Advisors
CBT Advisors CEO Steve Dickman has worked in consulting and venture capital for twenty years. He founded CBT Advisors in 2003 and has worked on storytelling and strategy with more than three hundred private biotechnology and life sciences clients. Much of the firm?s work focuses on drafting business sections for NASDAQ IPOs. Forty-three clients have gone public, raising $3.4 billion. IPO clients have included CRISPR Therapeutics, Karuna Therapeutics, Alector Inc., Black Diamond Therapeutics and others. Previously, Steve was a venture capitalist with TVM Capital, where his investments included Sirna Therapeutics, which was acquired in 2006 by Merck for $1.1 billion, and bluebird bio, which went public on Nasdaq (BLUE) in 2013. Steve publishes from time to time on Forbes.com
Seminars
This highly interactive and extended workshop offers a deep dive into the GLP-1 landscape, moving beyond clinical data to focus squarely on market opportunity, investor perception, and financial strategy. Attendees will gain practical insights on the most promising “Future of GLP-1” opportunities – from multi-agonists to neurobiology and novel indications – and learn how to translate these scientific concepts into compelling, fundable, and profitable business plans that capture commercial interest. The session integrates real-time audience surveys, displaying live results to benchmark audience sentiment against expert opinion, ensuring maximum engagement and direct relevance.
This workshop will gather experts to discuss:
- Evaluating the true peak sales potential and valuation drivers for next-generation GLP- 1s, including the financial impact of expanding into key indications like MASH, CKD and beyond to neurological disorders and addiction
- Utilizing interactive audience polls to assess which next-frontier innovations (e.g., muscle preservation, oral formulation, neurobiology) investors are actively prioritizing for the next five years
- Analyzing recent M&A and licensing activity in the cardiometabolic space to project which asset types and company profiles are most likely to be acquisition targets and the specific metrics currently driving those deals
- Demonstrating how companies can weave complex GLP-1 mechanisms into an attractive and robust business plan that secures executive and investor buy-in
- Tailoring funding roadmaps and communication strategies to attract different pools of capital (Venture vs. Public Equity) while navigating the stringent non-clinical criteria of investor due diligence
